Publications by authors named "P Gosi"
Article Synopsis
- Malaria remains a significant health issue in Thailand, particularly in border areas with mobile populations that facilitate its spread.
- A study of 112 Plasmodium falciparum isolates showed prevalent resistance mutations, including pfmdr1-Y184F and various pfk13 point mutations, linked to increased survival rates against treatment.
- The rise in resistant genotypes during 2014-2015 implies a connection with treatment failures in neighboring Cambodia, highlighting the need for coordinated efforts among countries to address malaria elimination.
Background: Newly emerged mutations within the Plasmodium falciparum chloroquine resistance transporter (PfCRT) can confer piperaquine resistance in the absence of amplified plasmepsin II (pfpm2). In this study, we estimated the prevalence of co-circulating piperaquine resistance mutations in P. falciparum isolates collected in northern Cambodia from 2009 to 2017.
View Article and Find Full Text PDFAtovaquone-proguanil remains effective against multidrug-resistant in Southeast Asia, but resistance is mediated by a single point mutation in cytochrome () that can arise during treatment. Among 14 atovaquone-proguanil treatment failures in a clinical trial in Cambodia, only one recrudescence harbored the mutation Y268C. Deep sequencing did not detect the mutation at baseline or in the first 3 days of treatment, suggesting that it arose Further sequencing across similarly found no low-frequency mutations that were up-selected from baseline to recrudescence.
View Article and Find Full Text PDFBackground: High rates of dihydroartemisinin-piperaquine (DHA-PPQ) treatment failures have been documented for uncomplicated Plasmodium falciparum in Cambodia. The genetic markers plasmepsin 2 (pfpm2), exonuclease (pfexo) and chloroquine resistance transporter (pfcrt) genes are associated with PPQ resistance and are used for monitoring the prevalence of drug resistance and guiding malaria drug treatment policy.
Methods: To examine the relative contribution of each marker to PPQ resistance, in vitro culture and the PPQ survival assay were performed on seventeen P.
Background: Primaquine is an approved radical cure treatment for Plasmodium vivax malaria but treatment can result in life-threatening hemolysis if given to a glucose-6-phosphate dehydrogenase deficient (G6PDd) patient. There is a need for reliable point-of-care G6PD diagnostic tests.
Objectives: To evaluate the performance of the CareStart™ rapid diagnostic test (RDT) in the hands of healthcare workers (HCWs) and village malaria workers (VMWs) in field settings, and to better understand user perceptions about the risks and benefits of PQ treatment guided by RDT results.